Patient Characteristics (n = 56)
| Characteristic | Data |
|---|---|
| Age (y) | 69 (64–74) |
| Eastern Cooperative Oncology Group status | |
| 0 or 1 | 49 (88) |
| 2 | 7 (12) |
| PSA at C1 (μg/L) | 115 (46–476) |
| Hemoglobin (reference range [RR], 130–180 g/L) | 122 (110–131) |
| Alkaline phosphatase (RR, 30–100 U/L) | 113 (86–231) |
| Albumin (RR, 36–52 g/L) | 38 (34–41) |
| De novo metastatic disease | 29 (52) |
| Gleason score | |
| ≤7 | 9 (16) |
| 8–10 | 35 (63) |
| Unknown/not available | 12 (21) |
| Prior systemic treatments | |
| Luteinizing hormone–releasing hormone agonist or antagonist | 56 (100) |
| Chemotherapy | 56 (100) |
| Docetaxel | 56 (100) |
| Cabazitaxel | 53 (91) |
| Other chemotherapy | 5 (9) |
| ASI | 56 (100) |
| Enzalutamide only | 27 (48) |
| Abiraterone only | 13 (23) |
| Abiraterone + enzalutamide | 16 (29) |
| Clinical trial medication | 4 (7) |
| PSMA PET | |
| SUVmean | 8 (7–10) |
| SUVmax | 39 (29–61) |
| Volume (L) | 0.64 (0.19–1.21) |
| 18F-FDG PET | |
| SUVmean | 4 (3–5) |
| SUVmax | 8 (5–10) |
| Volume (L) | 0.07 (0.02–0.31) |
| Disease volume | |
| <20 metastases | 19 (33) |
| ≥ 0 metastases | 37 (66) |
| Sites of disease on PSMA PET | |
| Bone | 49 (88) |
| Lymph node | 31 (55) |
| Viscera | 12 (21) |
Qualitative data are absolute counts and percentage; continuous data are median and interquartile range.